<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922776</url>
  </required_header>
  <id_info>
    <org_study_id>TILsOV-1805</org_study_id>
    <secondary_id>Id RCB</secondary_id>
    <nct_id>NCT03922776</nct_id>
  </id_info>
  <brief_title>Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer</brief_title>
  <acronym>TILsOV-1805</acronym>
  <official_title>Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Advanced High-grade Serous Ovarian Cancer in Blood, Ascites, Peritoneal Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocenter, interventional, non-randomized study among women patients with an
      ovarian or tubal cancer who will receive a surgery or adjuvant chemotherapy treatment, or a
      neo-adjuvant chemotherapy then surgery +/- adjuvant chemotherapy. The planned interventions
      are collection of biological samples at different times. The study will aim to describe the
      immunological profile at diagnosis in terms of phenotypic : PBMCs (peripheral blood,
      mononuclear cells) in peripheral blood, TILs (tumor-infiltrating lymphocytes) in ascites and
      in carcinomatosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive the following interventions because they are enrolled in the study:
      blood sample collection

        -  at diagnosis, before chemotherapy (pre-CT)

        -  after chemotherapy (post-ct)

      Two additional blood samples will be collected in each patient : one at diagnosis and one at
      the end of chemotherapy.

      The aim of this study is to describe the immunological profile at diagnosis in terms of
      phenotypic : PBMC in peripheral blood, TILs in ascites and in carcinomatosis, in patients
      treated for peritoneal carcinomatosis of ovarian or tubal origin. The treatment has to be a
      surgery and an adjuvant chemotherapy, or a neo-adjuvant chemotherapy followed by a surgery
      +/- adjuvant chemotherapy.

      Other objectives of the study include:

        -  Evaluate the association between the immunological profile at diagnosis and the
           characteristics of the disease at diagnosis (histological type, extension)

        -  Evaluate the prognostic value of the immunological profile at diagnosis in terms of
           clinical response to neoadjuvant chemotherapy (for patients with interval surgery)

        -  Evaluate the polarization of the immune response induced by chemotherapy, describing the
           phenotypic changes in the different types of samples (blood, +/- ascites, +/-
           carcinomatosis) after chemotherapy in comparison with samples at diagnostic

        -  Evaluate the association between these immunological phenotypic changes and the clinical
           response to chemotherapy in patients receiving neoadjuvant chemotherapy

        -  Collect biological material for peritoneal carcinomatosis for subsequent biological
           analyzes
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Counting of lymphocyte populations (pre-chemotherapy)</measure>
    <time_frame>At diagnosis (during diagnostic laparoscopy, which is : before chemotherapy (pre-CT) and up to 1 month after enrollment)</time_frame>
    <description>For each sample taken (blood / ascites / peritoneal carcinomatosis fragment), before chemotherapy, the lymphocyte populations will be counted by flow cytometry (CMF). For this, 4 panels of 32 markers will be used to identify 5 populations of lymphocytes: Thelper, B lymphocytes, TREG, TFH, TCD8, and immuno checkpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Counting of lymphocyte populations (post-chemotherapy)</measure>
    <time_frame>At the end of chemotherapy (post-CT), up to 3 months</time_frame>
    <description>For each sample taken (blood / ascites / peritoneal carcinomatosis fragment), at the end of chemotherapy, the lymphocyte populations will be counted by flow cytometry (CMF). For this, 4 panels of 32 markers will be used to identify 5 populations of lymphocytes: Thelper, B lymphocytes, TREG, TFH, TCD8, and immuno checkpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological type on the initial biopsy</measure>
    <time_frame>At diagnosis, before chemotherapy (pre-CT), up to 1 month after enrollment</time_frame>
    <description>To check if there is an extension to the pleura (FIGO-IV) or not (FIGO-IIIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response to chemotherapy (post-chemotherapy)</measure>
    <time_frame>At the end of chemotherapy, up to 3 months</time_frame>
    <description>In patients receiving neo-adjuvant chemotherapy, clinical response to chemotherapy defined by a partial or complete radiological response (assessed on the thoraco-abdominopelvic CT scan), associated with a decrease in CA125 and a disappearance of ascites in case of ascites at inclusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological response to chemotherapy (no residual disease on excised tissue)</measure>
    <time_frame>At the surgery, an average of 6 weeks after inclusion</time_frame>
    <description>Rate of patients with no residual disease on excised tissue regarding the assessment of histological response to chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months min to 14 months max</time_frame>
    <description>Time between the diagnosis and the progression of the disease or the death of the patient, whatever the cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global survival</measure>
    <time_frame>6 months min to 14 months max</time_frame>
    <description>Time between diagnosis and death, whatever the cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Ovarian Cancer Stage IIIC</condition>
  <condition>Fallopian Tube Cancer Stage IIIC</condition>
  <condition>Fallopian Tube Cancer Stage IV</condition>
  <condition>Ovarian Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>Blood sample collection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following interventions because they are enrolled in the study: blood sample collection
at diagnosis, before chemotherapy (pre-CT)
after chemotherapy (post-ct)
Intervention : Collection of two blood samples (5mL)
before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment
and then, after chemotherapy (post-CT), up to 3 months after enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Participants will receive the following interventions because they are enrolled in the study: blood sample collection
at diagnosis, before chemotherapy (pre-CT)
after chemotherapy (post-ct) Collection of two blood samples (5mL),
before chemotherapy (pre-CT), at diagnosis, up to 1 month after enrollment
and then, after chemotherapy (post-CT), up to 3 months after enrollment</description>
    <arm_group_label>Blood sample collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old or more

          -  Presenting a carcinomatosis with suspicion of ovarian cancer or tubal cancer, under a
             diagnostic laparoscopy

          -  Stage IIIC or initial pleural IV

          -  Planned treatment with surgery and adjuvant chemotherapy, or neo-adjuvant chemotherapy
             followed by surgery +/- adjuvant chemotherapy

          -  Having been informed and signed the informed consent of this study

          -  Affiliated with a social security scheme

        Exclusion Criteria:

          -  Stage IV with visceral metastases (pulmonary, hepatic ...)

          -  Contraindication to surgery and / or chemotherapy

          -  Pregnant or lactating woman

          -  Patient under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women in a study of ovarian cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine Hudry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Département de cancérologie uro-digestive - Centre Oscar Lambret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Vanseymortier</last_name>
    <phone>03 20 29 59 18</phone>
    <email>promotion@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delphine Hudry, MD</last_name>
    <phone>03.20.29.59.59</phone>
    <email>d-hudry@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine DH Hudry, MD</last_name>
      <phone>03 20 29 59 59</phone>
      <email>d-hudry@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>Eric EL Leblanc, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice FN Narducci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cyril CA Abdeddaim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick AC Chevalier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A. Sensitive and frequent identification of high avidity neo-epitope specific CD8 (+) T cells in immunotherapy-naive ovarian cancer. Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.</citation>
    <PMID>29545564</PMID>
  </reference>
  <reference>
    <citation>Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.</citation>
    <PMID>29754820</PMID>
  </reference>
  <reference>
    <citation>Mayor P, Starbuck K, Zsiros E. Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol. 2018 Aug;150(2):361-369. doi: 10.1016/j.ygyno.2018.05.024. Epub 2018 May 24. Review.</citation>
    <PMID>29803316</PMID>
  </reference>
  <reference>
    <citation>van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018 Jan 18;378(3):230-240. doi: 10.1056/NEJMoa1708618.</citation>
    <PMID>29342393</PMID>
  </reference>
  <reference>
    <citation>Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017 Nov 1;28(suppl_8):viii1-viii7. doi: 10.1093/annonc/mdx444. Review.</citation>
    <PMID>29232467</PMID>
  </reference>
  <reference>
    <citation>Tran E, Robbins PF, Rosenberg SA. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017 Feb 15;18(3):255-262. doi: 10.1038/ni.3682. Review.</citation>
    <PMID>28198830</PMID>
  </reference>
  <reference>
    <citation>Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Tołoczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf A, Ryan A, Chudecka-Głaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubiński J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Ursula E, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, Anna A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017 Dec 1;3(12):e173290. doi: 10.1001/jamaoncol.2017.3290.</citation>
    <PMID>29049607</PMID>
  </reference>
  <reference>
    <citation>Delcourt V, Franck J, Leblanc E, Narducci F, Robin YM, Gimeno JP, Quanico J, Wisztorski M, Kobeissy F, Jacques JF, Roucou X, Salzet M, Fournier I. Combined Mass Spectrometry Imaging and Top-down Microproteomics Reveals Evidence of a Hidden Proteome in Ovarian Cancer. EBioMedicine. 2017 Jul;21:55-64. doi: 10.1016/j.ebiom.2017.06.001. Epub 2017 Jun 3.</citation>
    <PMID>28629911</PMID>
  </reference>
  <reference>
    <citation>Murakami R, Matsumura N, Mandai M, Yoshihara K, Tanabe H, Nakai H, Yamanoi K, Abiko K, Yoshioka Y, Hamanishi J, Yamaguchi K, Baba T, Koshiyama M, Enomoto T, Okamoto A, Murphy SK, Mori S, Mikami Y, Minamiguchi S, Konishi I. Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. Am J Pathol. 2016 May;186(5):1103-13. doi: 10.1016/j.ajpath.2015.12.029. Epub 2016 Mar 15.</citation>
    <PMID>26993207</PMID>
  </reference>
  <reference>
    <citation>Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The &quot;cancer immunogram&quot;. Science. 2016 May 6;352(6286):658-60. doi: 10.1126/science.aaf2834.</citation>
    <PMID>27151852</PMID>
  </reference>
  <reference>
    <citation>Santoiemma PP, Powell DJ Jr. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16(6):807-20. doi: 10.1080/15384047.2015.1040960. Epub 2015 Apr 20. Review.</citation>
    <PMID>25894333</PMID>
  </reference>
  <reference>
    <citation>Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer. 2015 May 26;112(11):1782-90. doi: 10.1038/bjc.2015.145. Epub 2015 May 5.</citation>
    <PMID>25942397</PMID>
  </reference>
  <reference>
    <citation>Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.</citation>
    <PMID>25214542</PMID>
  </reference>
  <reference>
    <citation>Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30;5(24):12472-508. Review.</citation>
    <PMID>25537519</PMID>
  </reference>
  <reference>
    <citation>Tangye SG, Ma CS, Brink R, Deenick EK. The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol. 2013 Jun;13(6):412-26. doi: 10.1038/nri3447. Epub 2013 May 17. Review.</citation>
    <PMID>23681096</PMID>
  </reference>
  <reference>
    <citation>Bachmayr-Heyda A, Aust S, Heinze G, Polterauer S, Grimm C, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Pils D, Schuster E, Thalhammer T, Horvat R, Denkert C, Zeillinger R, Castillo-Tong DC. Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients--a study of the OVCAD consortium. BMC Cancer. 2013 Sep 17;13:422. doi: 10.1186/1471-2407-13-422.</citation>
    <PMID>24044611</PMID>
  </reference>
  <reference>
    <citation>Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.</citation>
    <PMID>22529265</PMID>
  </reference>
  <reference>
    <citation>Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012 Feb;124(2):192-8. doi: 10.1016/j.ygyno.2011.09.039. Epub 2011 Oct 29.</citation>
    <PMID>22040834</PMID>
  </reference>
  <reference>
    <citation>Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.</citation>
    <PMID>22204724</PMID>
  </reference>
  <reference>
    <citation>Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166. Erratum in: Nature. 2012 Oct 11;490(7419):298.</citation>
    <PMID>21720365</PMID>
  </reference>
  <reference>
    <citation>Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. Epub 2005 Dec 12.</citation>
    <PMID>16344461</PMID>
  </reference>
  <reference>
    <citation>Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004 Sep;10(9):942-9. Epub 2004 Aug 22.</citation>
    <PMID>15322536</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003 Jan 16;348(3):203-13.</citation>
    <PMID>12529460</PMID>
  </reference>
  <reference>
    <citation>Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002 Nov;3(11):991-8. Review.</citation>
    <PMID>12407406</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian cancer</keyword>
  <keyword>Tubal Cancer</keyword>
  <keyword>Immunological profile</keyword>
  <keyword>PBMc</keyword>
  <keyword>TILs</keyword>
  <keyword>Carcinomatosis</keyword>
  <keyword>HGSOC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

